Davoudian K, Bhattacharya S, Thompson D, Thompson M
Biomolecules. 2023; 13(9).
PMID: 37759826
PMC: 10527313.
DOI: 10.3390/biom13091426.
Choi J, Kim H, Kwon H, Lee E, Cho H, Chung J
Br J Cancer. 2023; 129(7):1184-1194.
PMID: 37596406
PMC: 10539369.
DOI: 10.1038/s41416-023-02355-2.
Turner J, Fredrickson M, DAntonio M, Katsnelson E, Macbeth M, Van Gulick R
Nat Commun. 2023; 14(1):3214.
PMID: 37270644
PMC: 10239450.
DOI: 10.1038/s41467-023-38933-4.
Torres R, Turner J, DAntonio M, Pelanda R, Kremer K
Immunol Rev. 2023; 317(1):203-222.
PMID: 37096808
PMC: 10523933.
DOI: 10.1111/imr.13208.
Dacheux M, Norman D, Tigyi G, Lee S
Pharmacol Ther. 2023; 245:108414.
PMID: 37061203
PMC: 10290275.
DOI: 10.1016/j.pharmthera.2023.108414.
Lysophosphatidic acid suppresses apoptosis of high-grade serous ovarian cancer cells by inducing autophagy activity and promotes cell-cycle progression EGFR-PI3K/Aurora-A-geminin dual signaling pathways.
Zhao H, Jia P, Nanding K, Wu M, Bai X, Morigen M
Front Pharmacol. 2023; 13:1046269.
PMID: 36601056
PMC: 9806123.
DOI: 10.3389/fphar.2022.1046269.
Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression.
Tang X, Cromwell C, Liu R, Godbout R, Hubbard B, McMullen T
Theranostics. 2022; 12(13):5675-5690.
PMID: 35966578
PMC: 9373824.
DOI: 10.7150/thno.66230.
Prognostic Value and Clinical Significance of LIPH in Breast Cancer.
Gao P, Liu Q, Ai B, Fang Y, Wang Z, Wang J
Int J Gen Med. 2021; 14:7613-7623.
PMID: 34754232
PMC: 8572048.
DOI: 10.2147/IJGM.S332233.
Lipid Profiling in Cancer Diagnosis with Hand-Held Ambient Mass Spectrometry Probes: Addressing the Late-Stage Performance Concerns.
Katz L, Tata A, Woolman M, Zarrine-Afsar A
Metabolites. 2021; 11(10).
PMID: 34677375
PMC: 8537725.
DOI: 10.3390/metabo11100660.
Lipid Phosphate Phosphatases and Cancer.
Tang X, Brindley D
Biomolecules. 2020; 10(9).
PMID: 32887262
PMC: 7564803.
DOI: 10.3390/biom10091263.
Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer.
Brindley D, Tang X, Meng G, Benesch M
Int J Mol Sci. 2020; 21(16).
PMID: 32824846
PMC: 7460696.
DOI: 10.3390/ijms21165938.
Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives.
Zulfikar S, Mulholland S, Adamali H, Barratt S
Clin Pharmacol. 2020; 12:97-108.
PMID: 32765123
PMC: 7367740.
DOI: 10.2147/CPAA.S228362.
Profiling lysophosphatidic acid levels in plasma from head and neck cancer patients.
Abdul Rahman M, Haron D, Hollows R, Abdul Ghani Z, Ali Mohd M, Chai W
PeerJ. 2020; 8:e9304.
PMID: 32547888
PMC: 7278886.
DOI: 10.7717/peerj.9304.
Regulation of Tumor Immunity by Lysophosphatidic Acid.
Lee S, Dacheux M, Norman D, Balazs L, Torres R, Augelli-Szafran C
Cancers (Basel). 2020; 12(5).
PMID: 32397679
PMC: 7281403.
DOI: 10.3390/cancers12051202.
Crossing signals: bioactive lipids in the microvasculature.
Chabowski D, Cohen K, Abu-Hatoum O, Gutterman D, Freed J
Am J Physiol Heart Circ Physiol. 2020; 318(5):H1185-H1197.
PMID: 32243770
PMC: 7541955.
DOI: 10.1152/ajpheart.00706.2019.
Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.
Benesch M, Tang X, Brindley D
Cancers (Basel). 2020; 12(2).
PMID: 32041123
PMC: 7072337.
DOI: 10.3390/cancers12020374.
Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer.
Yagi T, Shoaib M, Kuschner C, Nishikimi M, Becker L, Lee A
Cancers (Basel). 2019; 11(4).
PMID: 30979045
PMC: 6521627.
DOI: 10.3390/cancers11040520.
HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic.
Morin E, Li X, Schwendeman A
Front Endocrinol (Lausanne). 2018; 9:715.
PMID: 30555417
PMC: 6283888.
DOI: 10.3389/fendo.2018.00715.
Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
Radhakrishnan R, Ha J, Jayaraman M, Liu J, Moxley K, Isidoro C
Cancer Lett. 2018; 442:464-474.
PMID: 30503552
PMC: 7780843.
DOI: 10.1016/j.canlet.2018.11.023.
Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi G, Yue J, Norman D, Szabo E, Balogh A, Balazs L
Adv Biol Regul. 2018; 71:183-193.
PMID: 30243984
PMC: 6433480.
DOI: 10.1016/j.jbior.2018.09.008.
